Prudential Financial Inc Arvinas, Inc. Transaction History

Prudential Financial Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$36.38 - $52.31 $179,280 - $257,783	4,928 New	4,928 $203,000
Q2 2022 Aug 15, 2022	SELL	$36.01 - $74.24 $1.11 Million - $2.29 Million	-30,794 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$60.27 - $81.57 $361 - $489	-6 Reduced 0.02%	30,794 $2.07 Million
Q4 2021 Feb 14, 2022	BUY	$65.85 - $96.21 $649,807 - $949,400	9,868 Added 47.14%	30,800 $2.57 Million
Q3 2021 Nov 15, 2021	BUY	$73.2 - $107.87 $14,566 - $21,466	199 Added 0.96%	20,932 $1.78 Million
Q2 2021 Aug 16, 2021	BUY	$60.45 - $84.26 $31,434 - $43,815	520 Added 2.57%	20,733 $1.6 Million
Q1 2021 May 12, 2021	BUY	$58.19 - $91.37 $980,501 - $1.54 Million	16,850 Added 501.04%	20,213 $1.34 Million
Q4 2020 Feb 16, 2021	BUY	$20.19 - $84.93 $67,898 - $285,619	3,363 New	3,363 $286,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.